Antiemetics

Key Points

  • Multiple drug classes treat nausea/vomiting by targeting different neurotransmitter receptors in the chemoreceptor trigger zone (CTZ) and vomiting center
  • Ondansetron (Zofran): Serotonin antagonist — first-line for chemotherapy-induced nausea/vomiting (CINV) and postoperative nausea
  • Prochlorperazine: Dopamine antagonist — effective but causes extrapyramidal symptoms (EPS) with prolonged use
  • Metoclopramide: Prokinetic — speeds gastric emptying; risk of tardive dyskinesia with long-term use (Boxed Warning)
  • Meclizine: Antihistamine — first-line for motion sickness and vertigo
  • Scopolamine: Anticholinergic transdermal patch — motion sickness prevention; remove before MRI (metallic aluminized membrane)
  • Promethazine carries a severe pediatric respiratory-depression warning and should not be used in children younger than 2 years.

Pathophysiology of Nausea and Vomiting

The chemoreceptor trigger zone (CTZ), located in the area postrema of the brain, receives input from multiple pathways and is not restricted by the blood-brain barrier — allowing it to detect toxins in the bloodstream (e.g., opioids, chemotherapy agents, anesthesia).

CTZ receives input from:

  • GI tract (via cranial nerves IX and X) — distension, obstruction, inflammation
  • Vestibular system — motion sickness, vertigo
  • Cerebral cortex — odors, anxiety, pain
  • Bloodstream — drugs, toxins, metabolic disturbances

The CTZ activates the vomiting center in the medulla → retro-peristaltic contractions + abdominal muscle contraction → emesis.

Vomiting-center pathway map showing CTZ and receptor inputs from GI tract, vestibular system, and cortex Illustration reference: OpenRN Nursing Pharmacology 2e Ch.7.5.

Escalation red flags: vomiting >24 hours, hematemesis, severe abdominal pain, severe headache/stiff neck, or worsening dehydration signs.

Drug Classes and Mechanisms

NeurotransmitterDrug ClassPrototypeMechanism
Serotonin (5-HT3)Serotonin antagonistsOndansetronBlocks 5-HT3 in GI tract, CTZ, and vomiting center
Dopamine (D2)Dopamine antagonistsProchlorperazineBlocks dopamine in CTZ
Dopamine + AChProkineticsMetoclopramideBlocks dopamine in CTZ + stimulates ACh in GI tract
Histamine (H1)AntihistaminesMeclizineBlocks H1 receptors → blocks ACh in vestibular system
Acetylcholine (M1)AnticholinergicsScopolamineBlocks ACh receptors in vestibular system
Substance P (NK1)Neurokinin antagonistsAprepitantBlocks NK1 receptors — used for CINV
Cannabinoid (CB1)THCDronabinolActivates CB1 receptor — inhibitory effect on CTZ

Serotonin Antagonists (5-HT3 Antagonists)

Ondansetron (Zofran): Most widely used antiemetic in clinical practice.

Indications: Chemotherapy-induced nausea and vomiting (CINV), postoperative nausea and vomiting (PONV), radiation-induced nausea.

Advantages: Excellent safety profile; does not cause sedation or EPS; safe in pregnancy (used for hyperemesis gravidarum).

Routes: Oral, ODT (orally disintegrating tablet), IV, IM. Common pregnancy-context dosing reference: 4-8 mg every 8 hours as prescribed. IV timing profile: Onset often within about 15 minutes, peak around 30 minutes, and duration about 4-8 hours. IV administration safety: Give by slow IV push per protocol (commonly over about 2-5 minutes in adult practice) and reassess IV-site patency during/after administration to reduce infiltration or extravasation risk.

Contraindications/major interactions: Contraindicated with apomorphine; serotonin syndrome risk rises with concurrent serotonergic agents (e.g., SSRIs).

Adverse Effects: Headache, constipation, QTc prolongation with IV use (monitor ECG in at-risk patients), hypersensitivity reactions (fever/chills/rash/breathing difficulty).


Dopamine Antagonists

Prochlorperazine (Compazine): Blocks dopamine D2 receptors in the CTZ.

Indications: Severe nausea and vomiting, migraine-associated nausea.

Routes: PO, IM, PR, IV.

Contraindication (pediatrics): Avoid in children under 2 years old or under 20 lb.

Adverse Effects:

  • Extrapyramidal Symptoms (EPS): Akathisia, dystonia, drug-induced parkinsonism — especially with prolonged use
  • Sedation, orthostatic hypotension
  • Tardive dyskinesia (long-term use)
  • Photosensitivity and pink-to-reddish-brown urine can occur

Teaching: Avoid alcohol and other CNS depressants; use caution in extreme temperatures.

Phenothiazine Safety Alerts

  • Promethazine: Severe respiratory depression and death can occur in children younger than 2 years (boxed warning).
  • Chlorpromazine/Prochlorperazine: In older adults with dementia-related psychosis, antipsychotic exposure is associated with increased mortality risk.
  • Phenothiazines can worsen orthostatic hypotension and sedation; apply fall-risk precautions and reassess hemodynamic tolerance.

Prokinetics — Metoclopramide (Reglan)

Mechanism: Blocks dopamine D2 receptors in the CTZ AND stimulates acetylcholine receptors in the GI tract → accelerates gastric emptying.

Indications: Diabetic gastroparesis, GERD, PONV, N/V when gastric emptying delay is a component.

Onset by route: IV 1-3 minutes, IM 10-15 minutes, PO 30-60 minutes; effects usually persist 1-2 hours.

Important contraindications:

  • Do not use when increased GI motility is dangerous (GI hemorrhage, mechanical obstruction, perforation)
  • Contraindicated in pheochromocytoma (risk of hypertensive crisis)
  • Avoid in epilepsy or with other EPS-provoking medications when possible

Metoclopramide Boxed Warning — Tardive Dyskinesia

Tardive dyskinesia (irreversible involuntary movements) has been reported with metoclopramide. Risk increases with duration of use and cumulative dose. Avoid use >12 weeks unless clinical benefit outweighs risk.

Adverse Effects: EPS, drowsiness, fatigue, restlessness (akathisia), depression/suicidal ideation risk (especially with prolonged use), rare neuroleptic malignant syndrome.

Urgent teaching point: Report involuntary movements immediately (lip smacking, tongue thrusting, abnormal eye/limb movements).


Antihistamines

Meclizine (Antivert): Blocks H1 receptors, secondarily blocking acetylcholine in the vestibular system.

Indications: Motion sickness (first-line), vertigo associated with vestibular disorders.

Nursing considerations: Start about 1 hour before travel for motion-sickness prevention. Avoid use in glaucoma or enlarged prostate.

Adverse Effects: Drowsiness, dry mouth, blurred vision, constipation — classic anticholinergic effects.

Teaching: Avoid alcohol/sedatives; use caution with driving or machinery.

Hydroxyzine (Vistaril): First-generation H1 antagonist with antiemetic/anticholinergic effects used in anesthesia-associated, motion-related, and pregnancy-associated nausea pathways.

  • Injectable hydroxyzine should be given by deep IM route into a large muscle (for example gluteal in adults; vastus lateralis in pediatric pathways).
  • Monitor sedation burden and anticholinergic effects when co-administered with other CNS-active medications.

Dimenhydrinate: First-generation antihistamine option used in motion-related nausea and selected postoperative nausea pathways.

  • Common adverse effects include drowsiness, dry mouth, and dizziness.
  • Use fall-risk and sedation precautions when combined with other CNS depressants.

Pyridoxine-Doxylamine Combination (Pregnancy Nausea)

This combination is commonly used as first-line pharmacologic treatment when nonpharmacologic nausea measures are insufficient in pregnancy.

  • Typical administration pattern: Often started as bedtime dosing, with additional daytime doses per prescription if symptoms persist.
  • Mechanism pair: Pyridoxine (vitamin B6 support) plus doxylamine (H1-antihistamine/anticholinergic anti-nausea effect).
  • Important caution: Avoid concurrent MAOI therapy due to interaction risk.
  • Common side effects: Drowsiness, dry mouth/throat, dizziness.

Anticholinergics

Scopolamine (Transderm Scōp): Transdermal patch releasing ~1 mg over 3 days.

Application: Apply to hairless skin behind the ear (postauricular area). Only one patch at a time; do not cut the patch.

  • For motion-sickness prevention, apply about 4 hours before travel when prescribed.

Indications: Prevention of motion sickness, postoperative nausea (associated with anesthesia and opioids).

MRI Contraindication

Scopolamine transdermal patches contain an aluminized membrane — remove before MRI to prevent skin burns at application site.

Adverse Effects: Dry mouth, blurred vision, drowsiness, confusion and memory impairment (especially in older adults), urinary retention.

Contraindication: Narrow-angle glaucoma.

Teaching: Use gloves for application/removal when feasible, fold patch adhesive-to-adhesive for disposal per policy, wash hands after handling, and avoid hazardous tasks (e.g., driving/operating machinery) until individual response is known.


Neurokinin Receptor Antagonists

Aprepitant: Commonly used with dexamethasone plus ondansetron for CINV/PONV prevention pathways.

Rolapitant: Oral NK1 antagonist option used before chemotherapy to help prevent acute and delayed CINV.

Major interaction points:

  • Clinically significant CYP3A4 interactions (e.g., pimozide, diltiazem, rifampin)
  • Can lower warfarin INR effect; increase INR monitoring when co-administered
  • Can reduce efficacy of oral contraceptives; use backup birth control

Common adverse effects: Fatigue, dizziness, constipation, decreased appetite.


THC (Dronabinol/Medical Marijuana)

Use case: Refractory chemotherapy-associated nausea/vomiting (or cancer/AIDS-related nausea and appetite loss) when other antiemetic options are insufficient.

Nursing considerations:

  • Psychoactive and dose-related CNS effects (elation, altered perception, impaired coordination)
  • In older adults, start low and titrate cautiously due to higher sensitivity and postural hypotension risk
  • Habit-forming potential; counsel on safety and secure storage
  • Use caution in pregnancy and breastfeeding due to potential fetal/neurodevelopmental risk.

Teaching: Do not drive/operate machinery while affected.

For chemotherapy-associated nausea, ondansetron-centered pathways can reduce CNS-depression and infusion-site irritation burden compared with older phenothiazine antiemetic strategies.

Nursing Assessment

Before Administration:

  • Identify the cause of nausea/vomiting — target treatment to the cause
  • Assess hydration status: skin turgor, mucous membranes, urine output and color, blood pressure, heart rate
  • Lab values if ordered: Hgb, Hct, serum sodium (dehydration markers)
  • Document frequency, amount, and character of emesis

During/After Administration:

  • Monitor for improvement in nausea and frequency of vomiting
  • Assess for adverse effects (EPS with prochlorperazine/metoclopramide)
  • Monitor continued fluid balance
  • Report persistent vomiting >24 hours, hematemesis, severe abdominal pain, or severe headache with stiff neck

Patient Education — Nonpharmacological Measures:

  • Drink small sips of clear liquids frequently — avoid large amounts
  • Eat bland foods; avoid spicy, fatty, or salty foods
  • Eat smaller, more frequent meals
  • Avoid strong smells that trigger nausea
  • Prefer room-temperature meals/fluids and avoid high-bulk meals when nausea is active
  • Use adjunct relaxation and music-therapy strategies to reduce symptom intensity
  • Consider peppermint-oil aromatherapy as an adjunct when compatible with facility policy and patient preference
  • For morning sickness: eat plain crackers before rising
  • Adjunct options sometimes used in pregnancy-related nausea include ginger (up to 2 g/day in divided doses) and pyridoxine 10-25 mg every 8 hours when clinically appropriate

Self-Check

  1. A patient undergoing chemotherapy develops severe nausea. Which antiemetic class (and specific drug) is first-line for chemotherapy-induced nausea, and what is its mechanism?
  2. A patient who has been taking metoclopramide for 6 months develops repetitive lip-smacking movements and tongue thrusting. What adverse effect has occurred, and what is its significance?
  3. A patient with a scopolamine patch is scheduled for an MRI. What action must the nurse take before the scan, and why?